PLRX
vs
S&P 500
PLRX
S&P 500
Over the past 12 months, PLRX has underperformed S&P 500, delivering a return of -21% compared to the S&P 500's +17% growth.
Stocks Performance
PLRX vs S&P 500
Performance Gap
PLRX vs S&P 500
Performance By Year
PLRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Pliant Therapeutics Inc
Glance View
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 91 full-time employees. The company went IPO on 2020-06-03. The firm is focused on discovering and developing therapies for the treatment of fibrosis and related diseases. The company focuses in treating fibrosis by inhibiting integrin-mediated activation of transforming growth factor beta (TGF-B). Its lead product candidate, PLN-74809, is an oral small-molecule, dual-selective inhibitor of avß6 and avB1. The Company’s second product candidate, PLN-1474, is a small-molecule, selective inhibitor of avB1 for treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition to its clinical programs, it is developing additional preclinical integrin-based programs. The first preclinical program is oncology program. Its second preclinical program is an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor being developed for treatment of muscular dystrophies, including duchenne muscular dystrophy.
